Altimmune (ALT) Shares Outstanding (2010 - 2026)

Altimmune (ALT) has 17 years of Shares Outstanding data on file, last reported at $130.2 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $130.2 million, up 67.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $130.2 million (up 67.32% YoY), and the FY2025 annual result was $110.9 million, up 53.25% from the prior year.
• Shares Outstanding grew to $130.2 million in Q1 2026 per ALT's latest filing, from $110.9 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $130.2 million in Q1 2026 and troughed at $43.2 million in Q1 2022.
• A 5-year average of $70.5 million and a median of $70.9 million in 2024 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2024 and 2026: Shares Outstanding increased 2.37% in 2024, then jumped 67.32% in 2026.
• A 5-year view of Shares Outstanding shows it stood at $49.2 million in 2022, then jumped by 43.65% to $70.7 million in 2023, then advanced by 2.37% to $72.4 million in 2024, then jumped by 53.25% to $110.9 million in 2025, then grew by 17.44% to $130.2 million in 2026.
• Business Quant data shows ALT's Shares Outstanding at $130.2 million in Q1 2026, $110.9 million in Q4 2025, and $95.6 million in Q3 2025.